These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38282861)
1. Comparison design and evaluation power in cohort and self-controlled case series designs for post-authorization vaccine safety studies. Sato S; Kawazoe Y; Katsuta T; Fukuda H PeerJ; 2024; 12():e16780. PubMed ID: 38282861 [TBL] [Abstract][Full Text] [Related]
2. Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety. Li R; Stewart B; Weintraub E J Biopharm Stat; 2016; 26(4):686-93. PubMed ID: 26098696 [TBL] [Abstract][Full Text] [Related]
4. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. Takeuchi Y; Shinozaki T; Matsuyama Y BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575 [TBL] [Abstract][Full Text] [Related]
5. Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design. Lai LY; Arshad F; Areia C; Alshammari TM; Alghoul H; Casajust P; Li X; Dawoud D; Nyberg F; Pratt N; Hripcsak G; Suchard MA; Prieto-Alhambra D; Ryan P; Schuemie MJ Front Pharmacol; 2022; 13():837632. PubMed ID: 35392566 [TBL] [Abstract][Full Text] [Related]
6. [Self-controlled case-series (SCCS) method as a tool for the evaluation on the safety of vaccine]. Pan JR; He HQ; Yan R; Fu J Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Aug; 34(8):836-9. PubMed ID: 24423775 [TBL] [Abstract][Full Text] [Related]
7. Bias correction of risk estimates in vaccine safety studies with rare adverse events using a self-controlled case series design. Zeng C; Newcomer SR; Glanz JM; Shoup JA; Daley MF; Hambidge SJ; Xu S Am J Epidemiol; 2013 Dec; 178(12):1750-9. PubMed ID: 24327463 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
9. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales. Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598 [TBL] [Abstract][Full Text] [Related]
10. Safety of Vaccines Used for Routine Immunization in the United States. Maglione MA; Gidengil C; Das L; Raaen L; Smith A; Chari R; Newberry S; Hempel S; Shanman R; Perry T; Goetz MB Evid Rep Technol Assess (Full Rep); 2014 Jul; (215):1-740. PubMed ID: 30257278 [TBL] [Abstract][Full Text] [Related]
11. Ocular Adverse Events after Coronavirus Disease 2019 mRNA Vaccination: Matched Cohort and Self-Controlled Case Series Studies Using a Large Database. Hashimoto Y; Yamana H; Iwagami M; Ono S; Takeuchi Y; Michihata N; Uemura K; Yasunaga H; Aihara M; Kaburaki T Ophthalmology; 2023 Mar; 130(3):256-264. PubMed ID: 36306975 [TBL] [Abstract][Full Text] [Related]
12. Self-controlled case series design in vaccine safety: a systematic review. Nie X; Xu L; Bai Y; Liu Z; Liu Z; Farrington P; Zhan S Expert Rev Vaccines; 2022 Mar; 21(3):313-324. PubMed ID: 34937500 [TBL] [Abstract][Full Text] [Related]
14. The use of relative incidence ratios in self-controlled case series studies: an overview. Hawken S; Potter BK; Little J; Benchimol EI; Mahmud S; Ducharme R; Wilson K BMC Med Res Methodol; 2016 Sep; 16(1):126. PubMed ID: 27664070 [TBL] [Abstract][Full Text] [Related]
15. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885 [TBL] [Abstract][Full Text] [Related]
16. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. Glanz JM; McClure DL; Xu S; Hambidge SJ; Lee M; Kolczak MS; Kleinman K; Mullooly JP; France EK J Clin Epidemiol; 2006 Aug; 59(8):808-18. PubMed ID: 16828674 [TBL] [Abstract][Full Text] [Related]
17. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Baker MA; Lieu TA; Li L; Hua W; Qiang Y; Kawai AT; Fireman BH; Martin DB; Nguyen MD Am J Epidemiol; 2015 Apr; 181(8):608-18. PubMed ID: 25769306 [TBL] [Abstract][Full Text] [Related]
18. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766 [TBL] [Abstract][Full Text] [Related]
19. Allergic reactions to Japanese encephalitis vaccine. Plesner AM Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386 [TBL] [Abstract][Full Text] [Related]
20. Comparison of epidemiologic methods for active surveillance of vaccine safety. McClure DL; Glanz JM; Xu S; Hambidge SJ; Mullooly JP; Baggs J Vaccine; 2008 Jun; 26(26):3341-5. PubMed ID: 18462849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]